AbbVie (NYSE:ABBV) Trading Down 5.1% - Here's Why

Key Points

• Shares fell 5.1% on heavy volume and slipped below the 50‑day moving average after headlines that Johnson & Johnson won FDA approval for Icotyde, the first oral IL‑23 blocker, creating direct competition for AbbVie’s Skyrizi and pressuring dermatology revenue.
• AbbVie still reported a quarterly beat (EPS $2.71 vs. $2.65), set FY2026 guidance, and carries an average analyst rating of "Moderate Buy" with an average price target of $253.15.
• The company also signed a multi‑year collaboration with Alloy Therapeutics and rolled out a Skin Quality Index through Allergan Aesthetics, moves that can provide near‑term non‑dilutive revenue and support longer‑term pipeline and non‑Rx diversification.

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) fell 5.1% on Wednesday . The stock traded as low as $207.60 and last traded at $208.4740. 8,587,922 shares changed hands during trading, an increase of 21% from the average session volume of 7,091,849 shares. The stock had previously closed at $219.76.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie signed a multi‑year collaboration with Alloy Therapeutics to advance a novel antibody discovery platform, which provides near‑term non‑dilutive revenue and supports long‑term pipeline expansion. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: Allergan Aesthetics launched a Skin Quality Index to standardize aesthetics offerings — a strategic initiative that can help grow AbbVie’s Allergan franchise and support non‑Rx revenue diversification. AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
• Positive Sentiment: Some analysts and long‑term investors remain constructive: William Blair reiterated optimism around AbbVie’s obesity program and growth prospects, and notable investors continue to hold positions, supporting longer‑term confidence. William Blair Asserts AbbVie Inc. Growth Prospects on Obesity Treatment Opportunities
• Neutral Sentiment: Industry pricing politics remain active: Reuters found the TrumpRx price list does not universally undercut U.K. prices, a development that keeps drug‑pricing reform in focus but is not specific to AbbVie’s immediate earnings. TrumpRx lists many medicines at prices higher than paid in UK
• Negative Sentiment: Major near‑term negative: Johnson & Johnson won FDA approval for Icotyde, the first oral IL‑23 blocker, creating direct competition for AbbVie’s Skyrizi and threatening future dermatology revenue. Analysts warn peak sales could be materially affected. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: coverage and headlines about J&J’s approval triggered heavy selling and technical pressure; ABBV slipped below its 50‑day moving average, signaling short‑term momentum deterioration for traders. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
• Negative Sentiment: Legal risk persists after a U.S. appeals court revived a whistleblower lawsuit accusing big drugmakers of overcharging government programs, which could create litigation exposure for major pharma firms including AbbVie. Big drugmakers must face US overcharge claims on medications for low-income patients

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABBV shares. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Piper Sandler boosted their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an "overweight" rating in a research report on Wednesday, February 18th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research note on Tuesday, January 20th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a report on Thursday, February 5th. Finally, HSBC upgraded shares of AbbVie from a "hold" rating to a "buy" rating and lifted their price objective for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and an average price target of $253.15.

AbbVie Price Performance

The firm's 50 day moving average is $224.27 and its 200 day moving average is $224.95. The company has a market cap of $368.62 billion, a PE ratio of 88.34, a PEG ratio of 0.77 and a beta of 0.34.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period last year, the firm earned $2.16 EPS. The business's quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.08% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. State Street Corp boosted its holdings in shares of AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company's stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares during the period. Geode Capital Management LLC grew its stake in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company's stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in AbbVie by 6.0% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock valued at $4,970,848,000 after purchasing an additional 1,517,222 shares during the period. Finally, Bank of America Corp DE raised its position in AbbVie by 1.4% during the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company's stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.